Antonio Cuneo
A5062047451- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Eosinophilic Disorders and Syndromes
- Viral-associated cancers and disorders
- Cancer-related Molecular Pathways
- Hematopoietic Stem Cell Transplantation
- Gastrointestinal Tumor Research and Treatment
- Multiple Myeloma Research and Treatments
- Retinoids in leukemia and cellular processes
- Glycosylation and Glycoproteins Research
- Hemoglobinopathies and Related Disorders
- Monoclonal and Polyclonal Antibodies Research
- Genomic variations and chromosomal abnormalities
- CNS Lymphoma Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Kruppel-like factors research
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
University of Ferrara
2016-2025
Arcispedale Sant'Anna
2015-2024
Centre for Research and Technology Hellas
2023
National and Kapodistrian University of Athens
2023
IRCCS Ospedale San Raffaele
2023
St. Anna Hospital
2008-2022
Weatherford College
2022
Ospedale Sant'Anna
2004-2020
Hudson Institute
2019
John Wiley & Sons (United States)
2019
Several small studies on patients with COVID-19 and haematological malignancies are available showing a high mortality in this population. The Italian Hematology Alliance aimed to collect data from adult who required hospitalisation for COVID-19.This multicentre, retrospective, cohort study included (aged ≥18 years) diagnosis of WHO-defined malignancy admitted 66 hospitals between Feb 25 May 18, 2020, laboratory-confirmed symptomatic COVID-19. Data cutoff analysis was June 22, 2020. primary...
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study characterize course COVID-19 in and identify potential predictors outcome. Of 190 confirmed diagnosed between 28/03/2020 22/05/2020, 151 (79%) presented (need oxygen and/or intensive care admission). Severe was associated advanced...
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility there is no consensus the role of new markers. aim this project was to identify reproducible markers recommended diagnosis CLL. ERIC/ESCCA members classified 14 35 potential as “required” or “recommended” diagnosis, being defined >75% >50% agreement, respectively. An approach validate using normal peripheral blood developed. Responses were received from...
Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before receipt ruxolitinib may predict drug discontinuation in and reasons for discontinuation, phase at salvage therapies influence outcome. Methods A centralized electronic clinical database was created 20 European hematology centers, including laboratory data 524 who received myelofibrosis. Results At 3 years, 40.8% had...
In a phase II trial, we evaluated chlorambucil and rituximab (CLB‐R) as first‐line induction treatment with or without R maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28‐day cycles CLB (8 mg/m 2 /day, days 1–7) (day 1 cycle 3, 375 ; 4–8, 500 ). Responders were randomized to 12 8‐week doses (375 ) observation. As per intention‐to‐treat analysis, 82.4% (95% CI, 74.25–90.46%) 85 patients achieved an overall response (OR), 16.5% complete (CR),...
Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on immunoglobulin heavy variable (IGHV) somatic hypermutation (SHM) status. In this study, we assessed nine recurrently mutated genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, and XPO1) pre-treatment samples from 4580 CLL, using time-to-first-treatment (TTFT) as primary end-point relation to IGHV SHM Mutations were detected 1588 (34.7%)...
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
Abstract The P2X7R is an ATP-gated cation channel expressed in hemopoietic cells that participates both cell proliferation and apoptosis. Expression function of the have been associated with clinical course patients affected by chronic lymphocytic leukemia (CLL). Functional variants causing loss-of-function identified, namely, polymorphisms 1513A&gt;C (E496A), 1729T&gt;A (I568N), 946G&gt;A (R307Q). Here we investigated other nonsynonymous located either extracellular portion...
Abstract Background Fludarabine, is one of the most active single agents in treatment chronic lymphocytic leukemia (CLL). Over time, however, virtually all CLL patients become fludarabine-refractory. To elucidate whether microRNAs are involved development fludarabine resistance, we analyzed expression 723 human miRNAs before and 5-days after mono-therapy 17 which were classified as responder or refractory to based on NCI criteria. Results By comparing profiles these two groups patients,...
In patients with Myelofibrosis (MF) treated ruxolitinib (RUX), the response is unpredictable at therapy start. We retrospectively evaluated impact of clinical/laboratory factors on responses in 408 RUX according to prescribing obligations 18 Italian Hematology Centers. At 6 months, 114 out 327 (34.9%) evaluable achieved a spleen response. By multivariable Cox proportional hazard regression model, pre-treatment negatively correlating were: high/intermediate-2 IPSS risk (p=0.024), large...
is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of